BioSpace News Archive

Fact.MR, a global research & consulting firm, in their updated edition of the report, states that the colored contact lenses market is projected to record a robust growing pace in 2021 & beyond.

The catheters that are utilized to access the patient’s vascular system through veins are known as intravenous catheters. These catheters are thin tubes that are used to serve various medical purposes such as use in administration of medications, surgical procedures, removal of body fluids, and treating diseases.

Aging is characterized by a progression in losing of physiological integrity and function over time.

Neurological diseases have affected millions around the globe, and are known to be one of the worst kinds of maladies that can strike absolutely anyone.

Umbralisib (UKONIQ™) granted accelerated approval by US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL), follicular lymphoma (FL).

Certara, the global leader in biosimulation, today announced that it has published a white paper on how biosimulation can be used to optimize the world’s limited supply of COVID-19 vaccines.

Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -274 trial, which showed that Opdivo (nivolumab) significantly improved disease-free survival (DFS) as an adjuvant treatment across all randomized patients with surgically resected,

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced the commencement of a proposed underwritten public offering of 2,891,322 of its ordinary shares by certain non-officer, non-director shareholders (the “selling shareholders”).

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), announces that it has filed a Form 51-102F4 Business Acquisition Report (BAR) pursuant to National Instrument 51-102 Continuous Disclosure Obligations in connection with its acquisition of Psilocin Pharma Corp. on March 5, 2020.‎

RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (“Relief” or the “Company”) affirms that its collaboration partner NeuroRx, Inc. has initiated a phase 2/3 clinical trial investigating the role of inhaled RLF-100TM (aviptadil; ZYESAMI(TM)) for the treatment of patients with severe COVID-19 in partnership with UCI Health of the University of California, Irvine.